Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business ...(nt Vermillion is granted exclusive ...)

rights to the biomarker panel.

Ovarian Cancer Diagnostic Test Progress

-- Received the distinguished Society for Gynecologic Oncologists' (SGO)

Basic Science Poster Award for its abstract, "Prospective independent

validation of a marker panel for distinguishing benign from malignant

pelvic masses." The abstract, which demonstrated that the Company's

Ovarian Tumor Triage Test correctly identified 84 percent of ovarian

cancer cases, compared to only 33 percent identified using standard

diagnosis methods without the test, was presented at the SGO 38th

Annual Meeting on Women's Cancer last year in San Diego.

-- Completed enrollment of 550 patients at 27 medical centers in a

clinical trial to evaluate Vermillion's Ovarian Tumor Triage Test to

differentiate women with ovarian cancer from women with benign pelvic

masses.

-- Presented seven studies at the European Society for Gynecologic

Oncology meeting describing advancements in Vermillion's ovarian cancer

diagnostic program.

-- Data showed that Vermillion's panel of ovarian cancer protein

biomarkers in combination with CA-125 could more accurately identify

early-stage ovarian cancer than could CA-125 alone.

-- Data demonstrated that Vermillion's ovarian cancer biomarker panel

could accurately and with statistical significance predict women with

ovarian cancer who had good prognosis from those who did not. The study

used Kaplan-Meier analysis to show that women with a low panel score

were significantly more likely to survive than women with high scores,

independent of the stage of the disease.

Corporate Developments

-- Renewed a long-standing collaboration with Johns Hopkins University on

the development of novel biomarkers that can be applied towar
'/>"/>